Literature DB >> 32873593

Effects of Multiple Doses of Dichloroacetate on GSTZ1 Expression and Activity in Liver and Extrahepatic Tissues of Young and Adult Rats.

Edwin J Squirewell1, Marci G Smeltz1, Laura Rowland-Faux1, Lloyd P Horne1, Peter W Stacpoole1, Margaret O James2.   

Abstract

Glutathione transferase zeta 1 (GSTZ1), expressed in liver and several extrahepatic tissues, catalyzes dechlorination of dichloroacetate (DCA) to glyoxylate. DCA inactivates GSTZ1, leading to autoinhibition of its metabolism. DCA is an investigational drug for treating several congenital and acquired disorders of mitochondrial energy metabolism, including cancer. The main adverse effect of DCA, reversible peripheral neuropathy, is more common in adults treated long-term than in children, who metabolize DCA more quickly after multiple doses. One dose of DCA to Sprague Dawley rats reduced GSTZ1 expression and activity more in liver than in extrahepatic tissues; however, the effects of multiple doses of DCA that mimic its therapeutic use have not been studied. Here, we examined the expression and activity of GSTZ1 in cytosol and mitochondria of liver, kidney, heart, and brain 24 hours after completion of 8-day oral dosing of 100 mg/kg per day sodium DCA to juvenile and adult Sprague Dawley rats. Activity was measured with DCA and with 1,2-epoxy-3-(4-nitrophenoxy)propane (EPNPP), reported to be a GSTZ1-selective substrate. In DCA-treated rats, liver retained higher expression and activity of GSTZ1 with DCA than other tissues, irrespective of rodent age. DCA-treated juvenile rats retained more GSTZ1 activity with DCA than adults. Consistent with this finding, there was less measurable DCA in tissues of juvenile than adult rats. DCA-treated rats retained activity with EPNPP, despite losing over 98% of GSTZ1 protein. These data provide insight into the differences between children and adults in DCA elimination under a therapeutic regimen and confirm that the liver contributes more to DCA metabolism than other tissues. SIGNIFICANCE STATEMENT: Dichloroacetate (DCA) is one of few drugs exhibiting higher clearance from children than adults, after repeated doses, for reasons that are unclear. We hypothesized that juveniles retain more glutathione transferase zeta 1 (GSTZ1) than adults in tissues after multiple DCA doses and found this was the case for liver and kidney, with rat as a model to assess GSTZ1 protein expression and activity with DCA. Although 1,2-epoxy-3-(4-nitrophenoxy)propane was reported to be a selective GSTZ1 substrate, its activity was not reduced in concert with GSTZ1 protein.
Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Year:  2020        PMID: 32873593      PMCID: PMC7589944          DOI: 10.1124/dmd.120.000142

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  48 in total

1.  TRICHLOROETHYLENE, TETRACHLOROETHYLENE, AND SOME OTHER CHLORINATED AGENTS.

Authors: 
Journal:  IARC Monogr Eval Carcinog Risks Hum       Date:  2014

2.  Pharmacokinetics and metabolism of dichloroacetate in the F344 rat after prior administration in drinking water.

Authors:  A Gonzalez-Leon; I R Schultz; G Xu; R J Bull
Journal:  Toxicol Appl Pharmacol       Date:  1997-10       Impact factor: 4.219

3.  Regulation of dichloroacetate biotransformation in rat liver and extrahepatic tissues by GSTZ1 expression and chloride concentration.

Authors:  Stephan C Jahn; Marci G Smeltz; Zhiwei Hu; Laura Rowland-Faux; Guo Zhong; Ryan J Lorenzo; Katherine V Cisneros; Peter W Stacpoole; Margaret O James
Journal:  Biochem Pharmacol       Date:  2018-04-05       Impact factor: 5.858

Review 4.  Therapeutic applications of dichloroacetate and the role of glutathione transferase zeta-1.

Authors:  Margaret O James; Stephan C Jahn; Guo Zhong; Marci G Smeltz; Zhiwei Hu; Peter W Stacpoole
Journal:  Pharmacol Ther       Date:  2016-10-19       Impact factor: 12.310

5.  Systematic characterization of glutathione S-transferases in common marmosets.

Authors:  Yasuhiro Uno; Shotaro Uehara; Saki Tanaka; Norie Murayama; Hiroshi Yamazaki
Journal:  Biochem Pharmacol       Date:  2020-02-04       Impact factor: 5.858

6.  Development of a novel observer reported outcome tool as the primary efficacy outcome measure for a rare disease randomized controlled trial.

Authors:  Peter W Stacpoole; Jonathan Shuster; John L P Seamus Thompson; Robert A Prather; Lee Ann Lawson; Baiming Zou; Richard Buchsbaum; Sara Jo Nixon
Journal:  Mitochondrion       Date:  2017-11-10       Impact factor: 4.160

7.  Mitochondrion as a novel site of dichloroacetate biotransformation by glutathione transferase zeta 1.

Authors:  Wenjun Li; Margaret O James; Sarah C McKenzie; Nigel A Calcutt; Chen Liu; Peter W Stacpoole
Journal:  J Pharmacol Exp Ther       Date:  2010-09-30       Impact factor: 4.030

8.  The dichloroacetate dilemma: environmental hazard versus therapeutic goldmine--both or neither?

Authors:  Peter W Stacpoole
Journal:  Environ Health Perspect       Date:  2010-10-04       Impact factor: 9.031

9.  Peripheral neuropathy in rats exposed to dichloroacetate.

Authors:  Nigel A Calcutt; Veronica L Lopez; Arjel D Bautista; Leah M Mizisin; Brenda R Torres; Albert L Shroads; Andrew P Mizisin; Peter W Stacpoole
Journal:  J Neuropathol Exp Neurol       Date:  2009-09       Impact factor: 3.685

10.  Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin.

Authors:  H Boxenbaum
Journal:  J Pharmacokinet Biopharm       Date:  1980-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.